Trimel to Present at Upcoming Investor Conference

(firmenpresse) - TORONTO, ONTARIO -- (Marketwire) -- 06/11/12 -- Trimel Pharmaceuticals Corporation (TSX: TRL) ("Trimel" or "the Company") today announced today that executive management will participate in the Bloom Burton & Co. Healthcare Investor Conference to be held June 21, 2012 at the Toronto Board of Trade. Mr. Tom Rossi, President and Chief Operating Officer, and Mr Kenneth Howling, Chief Financial Officer, are scheduled to present an overview of the Company and its product pipeline at 2:00 pm EDT. The presentation materials will also be available on the Trimel website at .

For further information regarding Trimel Pharmaceuticals Corporation, please contact either Bruce Brydon, Chairman of the Board and Chief Executive Officer at (416) 679-0711 or Kenneth Howling, Chief Financial Officer at (416) 679-0536 or via email at .

About Trimel

Trimel Pharmaceuticals Corporation (TSX: TRL) - Developing medications for Female Sexual Health and conditions related to Aging, and Well Being. Trimel is developing multiple product opportunities, including CompleoTRT™, a bio-adhesive intranasal Testosterone gel currently in Phase III clinical testing in the United States. CompleoTRT™ is under investigation for the treatment of male hypogonadism, a condition commonly referred to as "Low T". For more information, please visit .



Contacts:
Trimel Pharmaceuticals Corporation
Kenneth Howling
Chief Financial Officer
(416) 679-0536

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: MARKETWIRE
Datum: 11.06.2012 - 15:48 Uhr
Sprache: Deutsch
News-ID 155141
Anzahl Zeichen: 0

contact information:
Town:

TORONTO, ONTARIO

Kategorie:

Healthcare

Diese Pressemitteilung wurde bisher 166 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Trimel to Present at Upcoming Investor Conference"
steht unter der journalistisch-redaktionellen Verantwortung von

Trimel Pharmaceuticals Corporation (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Trimel Announces Filing of NATESTO(TM) With Health Canada ...

TORONTO, ONTARIO -- (Marketwired) -- 01/26/15 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that it has filed a New Drug Submission with Health Canada for NATESTO™ (testosterone) nasal gel for replacement therapy in men for cond ...

Trimel Announces Closing of Exclusive Agreement for NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 12/09/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced the closing of the previously communicated agreement between its subsidiary, Trimel BioPharma SRL, and an affiliate of Endo International ...

Trimel Announces Issuance of Additional Patent Covering NATESTO(TM) ...

TORONTO, ONTARIO -- (Marketwired) -- 11/25/14 -- Trimel Pharmaceuticals Corporation (TSX: TRL) today announced that its technology partner Mattern Pharma AG has been granted an additional United States Patent in respect of NATESTO™ and its propri ...

Alle Meldungen von Trimel Pharmaceuticals Corporation